Advertisement

Investigational New Drugs

, Volume 25, Issue 1, pp 63–67 | Cite as

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer

  • Neelima Denduluri
  • James J. Lee
  • Janice Walshe
  • Arlene W. Berman
  • Ujala Vatas
  • Catherine K. Chow
  • Seth M. Steinberg
  • Michael C. Cox
  • Jennifer A. Low
  • Sandra M. SwainEmail author
Phase II Studies

Summary

Twelve patients with metastatic breast cancer previously exposed to taxanes were treated on a Phase II trial with ixabepilone. Eligible patients had histologically confirmed metastatic breast cancer with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), and adequate hematopoietic, renal, and hepatic function. Ixabepilone 8 mg/m2/day was given intravenously daily for 3 days for the first 3-week cycle and increased to 10 mg/m2/day for subsequent cycles if patients did not have hematologic or other toxicity after the first cycle. Patients continued treatment until progressive disease or unacceptable toxicity. Three, 29, and 33 of 65 cycles administered were at the 7 mg/m2, 8 mg/m2 and 10 mg/m2 dose levels respectively. Grade 4 leukopenia (n=1), grade 3 neutropenia (n=2), grade 2 neuropathy (n=3), and grade 2 transaminase elevation (n=2) were the most notable toxicities. Ten patients had stable disease for at least 6 weeks. No complete or partial responses were observed in 12 evaluable patients treated with ixabepilone daily for 3 days. Although ixabepilone was well-tolerated, the dose of 8–10 mg/m2 daily for 3 days is not an effective therapy in metastatic breast cancer previously exposed to taxanes.

Keywords

Docetaxel Metastatic Breast Cancer Filgrastim Pegfilgrastim Metastatic Setting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil GM, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMedGoogle Scholar
  3. 3.
    Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A et al (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169–1175PubMedGoogle Scholar
  4. 4.
    Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–5551PubMedCrossRefGoogle Scholar
  5. 5.
    Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413–1424PubMedGoogle Scholar
  6. 6.
    Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R). J Biol Chem 272:2534–2541PubMedCrossRefGoogle Scholar
  7. 7.
    Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437PubMedGoogle Scholar
  8. 8.
    Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22:2015–2025PubMedCrossRefGoogle Scholar
  9. 9.
    Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15:3149–3155PubMedGoogle Scholar
  10. 10.
    Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, Griffin T, Lebwohl DE, Liebes L, Muggia F, Horwitz SB (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289–1298PubMedCrossRefGoogle Scholar
  11. 11.
    Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21:1866–1873PubMedCrossRefGoogle Scholar
  12. 12.
    Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486–2493PubMedGoogle Scholar
  13. 13.
    Zhuang SH, Menefee M, Kotz H, Agrawal M, Poruchynsky M, Hung E, Zhan Z, Linehan WM, Bates SE, Fojo T (2004) A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol, 22:4550 (Abstracts 4550)Google Scholar
  14. 14.
    Thomas E, Tabernero J, Fornier M, Fumoleau P, Lluch A, Viens P, Vahdat L, Conte P, Peck R, Martin M (2003) A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). J Clin Oncol, 22:8 (Abstracts 30)CrossRefGoogle Scholar
  15. 15.
    Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK (2003) Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 14:1518–1524PubMedCrossRefGoogle Scholar
  16. 16.
    Roche H, Cure H, Bunnell C, Cognetti F, Mauriac E, Perez E, Miller K, Sparano R, Peck R, Yelle L (2003) A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. J Clin Oncol, 22:69 (Abstracts 69)CrossRefGoogle Scholar
  17. 17.
    Pavlick A, Millward M, Farrell K, Hamilton A, Broseus A, Haas N, Shore T, Jacquotte A, Colevas D, Muggia F (2004) A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol, 22:7542 (Abstracts 7542)Google Scholar
  18. 18.
    Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, Kraut M, Ettinger DS, Dawkins F, Erlichman C (2005) Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol 23:3069–3073PubMedCrossRefGoogle Scholar
  19. 19.
    Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726–2734PubMedCrossRefGoogle Scholar
  20. 20.
    Llombart Cussac A, Baselga J, Manikhas G, Kubista E, Steger G, Galbraith SM, Sullivan MA, Zerba K, Lee H, Gianni L (2005) Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol, 23:586 (Abstracts 586)Google Scholar
  21. 21.
    Hussain M, Faulkner J, Vaishampayan U, Lara P, Petrylak D, Colevas D, Sakr W, Crawford ED (2004) Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). J Clin Oncol, 22:4510 (Abstracts 4510)Google Scholar
  22. 22.
    Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, Vokes EE (2004) A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15:928–932PubMedCrossRefGoogle Scholar
  23. 23.
    Chen T, Molina A, Moore S, Goel S, Desai K, Hamilton A, Griffin T, Colevas AD, Mani S, Muggia F (2004) Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. J Clin Oncol, 22:2115 (Abstracts 2115)CrossRefGoogle Scholar
  24. 24.
    Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T (2005) A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 103:1932–1938PubMedCrossRefGoogle Scholar
  25. 25.
    Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642PubMedCrossRefGoogle Scholar
  26. 26.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  27. 27.
    National Cancer Institute Common toxicity criteria v 2.0 (April 30, 1999). Cancer therapy evaluation program. Bethesda, MD, National Cancer InstituteGoogle Scholar
  28. 28.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Neelima Denduluri
    • 1
  • James J. Lee
    • 2
  • Janice Walshe
    • 1
  • Arlene W. Berman
    • 1
  • Ujala Vatas
    • 1
  • Catherine K. Chow
    • 3
  • Seth M. Steinberg
    • 4
  • Michael C. Cox
    • 1
  • Jennifer A. Low
    • 5
  • Sandra M. Swain
    • 1
    Email author
  1. 1.Breast Cancer Section, Medical Oncology BranchCenter for Cancer Research, National Cancer Institute, National Institutes of HeathBethesdaUSA
  2. 2.Yale Cancer CenterYale University School of MedicineNew HavenUSA
  3. 3.Diagnostic Radiology DepartmentWarrant G. Magnuson Clinical Center, National Cancer Institute, National Institutes of HealthBethesdaUSA
  4. 4.Biostatistics and Data Management Section, Office of the Clinical DirectorCenter for Cancer Research, National Cancer Institute, National Institutes of HealthBethesdaUSA
  5. 5.Cancer Therapy Evaluation Program, Division of Cancer Treatment and DiagnosisNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations